🔴 BioCryst Pharmaceuticals is trading 4.2% down in pre-market with no clear company-specific catalyst identified

BioCryst Pharmaceuticals is trading 4.2% down now at $9.54 after no clear company-specific catalyst was identified for September 8, 2026.

• The latest company announcement was a September 1 investor-conference presentation scheduled for September 15, not a new earnings, regulatory, or corporate event.
• Broader sentiment is modestly risk-off, but the overall market decline does not clearly explain the move; recheck for delayed headlines or analyst actions.